专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明授权

US07001919B2 Forms of pravastatin sodium 失效
标题翻译：普伐他汀钠的形式
公开(公告)号：US07001919B2
公开(公告)日：2006-02-21
申请号：US09736796
申请日：2000-12-14
申请人： Vilmos Keri , Csaba Szabo , Edit Nagyne Arvai , Judith Aronhime
发明人： Vilmos Keri , Csaba Szabo , Edit Nagyne Arvai , Judith Aronhime
IPC分类号： A61K31/225 , C07C67/48 , C07C67/02
CPC分类号： C07C69/33 , A61K31/335 , C07C67/52 , C07C2602/28
摘要： New polymorphic forms of pravastatin sodium are provided. Each of the new forms is selectively obtained by crystallization from different solvent systems, each solvent system having a protic component, and by controlling the rate of crystallization through temperature. The new polymorphic forms are suitable for use as active substances of pharmaceutical dosage forms for reduction of serum cholesterol levels in the bloodstream.
摘要翻译：提供了普伐他汀钠的新型多晶型物质。通过从不同溶剂体系的结晶，每种溶剂体系具有质子成分，并通过控制通过温度的结晶速率来选择性地获得每种新形式。新的多晶型适用于药物剂型的活性物质，用于降低血液中的血清胆固醇水平。

82. 发明申请

US20050228007A1 Isoquinoline derivatives and methods of use thereof 审中-公开
标题翻译：异喹啉衍生物及其使用方法
公开(公告)号：US20050228007A1
公开(公告)日：2005-10-13
申请号：US11066824
申请日：2005-02-25
申请人： Prakash Jagtap , Erkan Baloglu , John Van Duzer , Csaba Szabo , Andrew Salzman , Aloka Roy , William Williams , Alexander Nivorozhkin
发明人： Prakash Jagtap , Erkan Baloglu , John Van Duzer , Csaba Szabo , Andrew Salzman , Aloka Roy , William Williams , Alexander Nivorozhkin
IPC分类号： A61K31/473 , A61K31/4745 , A61K31/55 , C07D221/18
CPC分类号： A61K31/473 , A61K31/4745 , A61K31/55 , C07D221/18
摘要： The present invention relates to Isoquinoline Derivatives, compositions comprising an effective amount of a Isoquinoline Derivative and methods for treating or preventing an inflammatory disease, a reperfusion injury, an ischemic condition, renal failure, diabetes, a diabetic complication, a vascular disease other than a cardiovascular disease, cardiovascular disease, reoxygenation injury resulting from organ transplantation, Parkinson's disease, or cancer, comprising administering to an animal in need thereof an effective amount of a Isoquinoline Derivative.
摘要翻译：本发明涉及异喹啉衍生物，包含有效量的异喹啉衍生物的组合物和治疗或预防炎性疾病，再灌注损伤，缺血状况，肾衰竭，糖尿病，糖尿病并发症，除心血管疾病，心脏病，由器官移植引起的再氧化损伤，帕金森病或癌症，包括向有需要的动物施用有效量的异喹啉衍生物。

83. 发明授权

US06936731B2 Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same 失效
标题翻译：普伐他汀钠基本上不含普伐他汀内酯和表皮普伐他汀，以及含有其的组合物
公开(公告)号：US06936731B2
公开(公告)日：2005-08-30
申请号：US09971746
申请日：2001-10-05
申请人： Vilmos Keri , Lajos Deak , Ilona Forgacs , Csaba Szabo , Arvai Edit Nagyne
发明人： Vilmos Keri , Lajos Deak , Ilona Forgacs , Csaba Szabo , Arvai Edit Nagyne
IPC分类号： A61K31/225 , C07C67/28 , C07C67/52 , C07C67/02 , C12P17/06
CPC分类号： C07C67/28 , A61K31/225 , C07C67/52 , C07C69/33
摘要： The present invention provides pravastatin sodium substantially free of pravastatin lactone and epiprava, the C-6 epimer of pravastatin. The present invention further provides a novel process for recovering pravastatin sodium from a fermentation broth in such high purity. The process includes the stages of forming an solution of the compound by extraction, obtaining an ammonium salt of pravastatin from the solution, purifying the ammonium salt of the compound and transposing the salt of the compound to pravastatin sodium.
摘要翻译：本发明提供基本上不含普伐他汀内酯和epiprava的普伐他汀钠，普伐他汀的C-6差向异构体。本发明进一步提供了一种以高纯度从发酵液中回收普伐他汀钠的新方法。该方法包括通过萃取形成化合物溶液的阶段，从溶液中获得普伐他汀铵盐，纯化化合物的铵盐并将化合物的盐转移至普伐他汀钠。

84. 发明授权

US06689590B2 Process for recovering statin compounds from a fermentation broth 失效
标题翻译：从发酵液中回收他汀类化合物的方法
公开(公告)号：US06689590B2
公开(公告)日：2004-02-10
申请号：US10200149
申请日：2002-07-23
申请人： Vilmos Keri , Lajos Deak , Iiona Forgacs , Csaba Szabo , Edit Arvai Nagyne
发明人： Vilmos Keri , Lajos Deak , Iiona Forgacs , Csaba Szabo , Edit Arvai Nagyne
IPC分类号： C12P762
CPC分类号： C12P17/06 , C07C67/52 , C07C69/013 , C07C69/33 , C07C2602/28 , C12P7/42
摘要： A composition comprising pravastatin sodium substantially free of pravastatin lactone is described.
摘要翻译：描述了包含基本上不含普伐他汀内酯的普伐他汀钠的组合物。

85. 发明授权

US06476048B1 Substituted phenanthridinones and methods of use thereof 失效
标题翻译：取代的菲啶酮及其使用方法
公开(公告)号：US06476048B1
公开(公告)日：2002-11-05
申请号：US09602539
申请日：2000-06-22
申请人： Csaba Szabo , Prakash Jagtap , Garry Southan , Andrew Salzman
发明人： Csaba Szabo , Prakash Jagtap , Garry Southan , Andrew Salzman
IPC分类号： A61K31473
CPC分类号： C07D279/02 , C07D221/12
摘要： This invention provides a novel class of substituted 6(5H)phenanthridinone compounds. Pharmaceutical compositions, and methods of making and using the compounds, or a pharmaceutically acceptable salt, hydrate, prodrug, or mixture thereof are also described.
摘要翻译：本发明提供了一类新的取代的6（5H）菲啶酮化合物。还描述了药物组合物，以及制备和使用化合物或其药学上可接受的盐，水合物，前药或其混合物的方法。

86. 发明授权

US06245921B1 Process for the isolation of pseudomonic acid A from pseudomonic acid complex-containing culture broth 失效
标题翻译：用于从含有假单胞菌酸的复合物的培养液中分离假单胞菌酸A的方法
公开(公告)号：US06245921B1
公开(公告)日：2001-06-12
申请号：US09497806
申请日：2000-02-03
申请人： Istvan Barta , Aniko Tegdes , Valeria Szell , Csaba Szabo , Edit Nagy Nee Arvai , Vilmos Keri , David Leonov , IIdiko Lang , Margit Bidlo Nee Igloy , Gyula Jerkovich , Janos Salat
发明人： Istvan Barta , Aniko Tegdes , Valeria Szell , Csaba Szabo , Edit Nagy Nee Arvai , Vilmos Keri , David Leonov , IIdiko Lang , Margit Bidlo Nee Igloy , Gyula Jerkovich , Janos Salat
IPC分类号： C07D31500
CPC分类号： C12P17/162
摘要： A process for the isolation of the pseudomonic acid A antibiotic of pharmaceutical quality from the culture broth of one of the pseudomonic acid A-producing species of the Pseudomonas bacterium genus comprising the extraction of the biosynthesized pseudomonic acid A from the culture broth at acidic pH with a chlorinated aliphatic hydrocarbon or isobutyl acetate, followed by purification, is disclosed. The invention includes processes for purification of the isolated pseudomonic acid A, including (a) by the distribution of the evaporated extract residue between the aqueous-alcohol and some aliphatic or aromatic hydrocarbon, and then the extraction of the increased water-containing aqueous-alcoholic phase with methylene chloride, ethyl acetate, or isobutyl acetate; (b) by the extraction of the extract with aqueous ammonium hydrogen carbonate, alkali metal hydroxide or ammonium hydroxide solution and the acidification of the resulting alkaline aqueous extract, then reextraction again with a chlorinated aliphatic hydrocarbon or isobutyl acetate; and (c) by the concentration of the extract and the recrystallization of the crystalline pseudomonic acid A in a mixture of isobutyl acetate and petroleum ether, or acetonitrile, or aqueous acetonitrile.
摘要翻译：从假单胞菌属的假单胞菌素A产生物种之一的培养液中分离出假单胞菌A抗生素药物质量的方法，包括在酸性pH下从培养液中提取生物合成的假单胞菌酸A，公开了氯化脂族烃或乙酸异丁酯，然后纯化。本发明包括纯化分离的假单胞菌酸A的方法，包括（a）通过在含水醇和某些脂族或芳族烃之间分配蒸发的提取物残渣，然后提取含水的含水醇与二氯甲烷，乙酸乙酯或乙酸异丁酯反应; （b）通过用碳酸氢铵水溶液，碱金属氢氧化物或氢氧化铵溶液萃取提取物，并将得到的碱性水提取物酸化，然后用氯化脂族烃或乙酸异丁酯再次萃取; 和（c）通过提取物的浓度和结晶假单胞菌酸A在乙酸异丁酯和石油醚或乙腈或乙腈水溶液的混合物中的重结晶。

87. 发明申请

US20130131096A1 8-HYDROXY-QUINOLINE DERIVATIVES 有权
标题翻译： 8-羟基喹啉衍生物
公开(公告)号：US20130131096A1
公开(公告)日：2013-05-23
申请号：US13696541
申请日：2011-05-06
申请人： Laszlo Puskas , Csaba Szabo , Ivan Kanizsai , Mario Gyuris , Ramona Madacsi , Bela Ozsvari , Liliana Feher , Gabor Tamas
发明人： Laszlo Puskas , Csaba Szabo , Ivan Kanizsai , Mario Gyuris , Ramona Madacsi , Bela Ozsvari , Liliana Feher , Gabor Tamas
IPC分类号： C07D413/12 , C07D401/14 , C07D401/10 , C07D401/12 , C07D215/26
CPC分类号： C07D413/12 , C07D215/26 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14
摘要： The invention relates to compounds of the general formula (I) and their pharmaceutically acceptable salts (in which formula R1 represents a hydrogen atom, lower alkyl group, lower alkenyl group, lower cycloalkyl group, aryl group, aralkyl group or heterocyclic group, wherein, the above groups are optionally substituted in ortho, meta and/or para position with 1, 2, 3 or 4 electron withdrawing groups or electron donating groups; R2 represents a hydrogen atom, lower alkyl group, aryl group, aralkyl group or heterocyclic group wherein the above groups are optionally substituted with one or more halogen atoms; R3 represents a lower alkyl group, aryl group, aralkyl group or heterocyclic group wherein the above groups are optionally substituted in ortho, meta or para position with 1, 2, 3 or 4 electron withdrawing groups or electron donating groups; R4 represents a hydrogen atom, lower alkyl group or any acidic functional group; n is 1 or 2). The compounds according to the invention can be used in the medicine mainly for the treatment of diseases associated with neurological and/or oxidative stress.
摘要翻译：本发明涉及通式（I）的化合物及其药学上可接受的盐（式中R1表示氢原子，低级烷基，低级烯基，低级环烷基，芳基，芳烷基或杂环基，其中，上述基团任选在邻位，间位和/或对位用1,2,3或4个吸电子基团或给电子基团取代; R 2表示氢原子，低级烷基，芳基，芳烷基或杂环基，其中上述基团任选被一个或多个卤素原子取代; R 3表示低级烷基，芳基，芳烷基或杂环基，其中上述基团在邻位，间位或对位任选被取代1,2,3或4 吸电子基团或给电子基团; R 4表示氢原子，低级烷基或任何酸性官能团; n为1或2）。根据本发明的化合物可用于药物中，主要用于治疗与神经和/或氧化应激有关的疾病。

88. 发明申请

US20110165268A1 Liquid Chalcogenide Compositions and Methods of Manufacturing and Using the Same 有权
标题翻译：液态硫族化合物组合物及其制造和使用方法
公开(公告)号：US20110165268A1
公开(公告)日：2011-07-07
申请号：US13049220
申请日：2011-03-16
申请人： Kevin J. Tomaselli , Paul A. Hill , Thomas L. Deckwerth , Edward Wintner , Csaba Szabo
发明人： Kevin J. Tomaselli , Paul A. Hill , Thomas L. Deckwerth , Edward Wintner , Csaba Szabo
IPC分类号： A61K33/04 , A61P43/00
CPC分类号： A61K33/04 , A61J1/06 , A61K9/0019 , A61K9/08 , A61K33/00 , A61K33/24 , A61K47/02 , A61K47/12 , B65D81/2069
摘要： The present invention provides novel stable, liquid compositions comprising chalcogenides or salts thereof. These compositions may be used for a variety of purposes, including the treatment and prevention of ischemic or hypoxic injury, as well as in the preservation of biological matter.
摘要翻译：本发明提供包含硫族化合物或其盐的新型稳定的液体组合物。这些组合物可以用于各种目的，包括治疗和预防缺血性或缺氧性损伤以及保护生物物质。

89. 发明申请

US20100183748A1 Methods for Treating or Preventing Radiocontrast Agent Induced Kidney Injury 审中-公开
标题翻译：治疗或预防放射治疗剂诱发肾损伤的方法
公开(公告)号：US20100183748A1
公开(公告)日：2010-07-22
申请号：US12690368
申请日：2010-01-20
申请人： Chienmin Su , Csaba Szabo
发明人： Chienmin Su , Csaba Szabo
IPC分类号： A61K33/04 , A61P43/00
CPC分类号： A61K33/04 , A61K9/0019 , A61K47/20
摘要： Methods for treating or preventing radiocontrast agent induced kidney injury in a mammal are disclosed, the methods comprising administering to the mammal a first effective amount of a chalcogenide composition prior to administering a radiocontrast agent to the mammal.
摘要翻译：公开了用于治疗或预防放射性对比剂诱导的哺乳动物肾损伤的方法，所述方法包括在向哺乳动物施用放射性对比剂之前向哺乳动物施用第一有效量的硫族化物组合物。

90. 发明授权

US07608714B2 Production of dolasetron 失效
标题翻译：多拉司琼的生产
公开(公告)号：US07608714B2
公开(公告)日：2009-10-27
申请号：US11650294
申请日：2007-01-05
申请人： Janos Hajko , Tivadar Tamas , Adrienne Kovacsne-Mezei , Erika Magyar Molnarne , Csaba Peto , Csaba Szabo
发明人： Janos Hajko , Tivadar Tamas , Adrienne Kovacsne-Mezei , Erika Magyar Molnarne , Csaba Peto , Csaba Szabo
IPC分类号： C07D221/22 , C07D451/00 , C07D455/00
CPC分类号： C07D471/18 , C07D303/40 , C07D451/14 , C07F7/1804
摘要： The present invention provides an improved process for the preparation of Dolasetron salts, in particularly Dolasetron mesylate. Also provided are intermediates for the process and methods of preparing the intermediates.
摘要翻译：本发明提供了制备Dolasetron盐的改进方法，特别是甲磺酸多拉司琼。还提供了制备中间体的方法和方法的中间体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式